Purpura fulminans;Purpura fulminans

Reanimation

Volumn 11, Issue 3, 2002, Pages 222-230

  Leclerc, F ^a   Noizet, O ^a   Dorkenoo, A E ^a   Cremer, R ^a   Leteurtre, S ^a   Sadik, A ^a   Fourier, C ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Child; Meningococcal infections; Purpura; Sepsis; Shock

Indexed keywords

AMOXICILLIN; CATECHOLAMINE; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; STEROID; TETRACOSACTIDE; VACCINE;

AMPUTATION; ANTIBIOTIC THERAPY; ECCHYMOSIS; FEVER; FLUID THERAPY; FULMINATING PURPURA; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTENSIVE CARE; ISCHEMIA; MENINGOCOCCOSIS; REVIEW; SEPSIS; SHOCK; SKIN GRAFT; SKIN NECROSIS;

EID: 0036091544     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1624-0693(02)00234-7     Document Type: Short Survey

References (56)

1. Acute infectious purpura fulminans: Pathogenesis and medical management
2. Update on meningococcal disease with emphasis on pathogenesis and clinical management
3. Les infections à méningocoque en France en 1998 et 1999
4. The early management of meningococcal disease
5. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin in children with meningococcal septic shock
6. Do new strategies in meningococcemia produce better outcomes?
7. Are there specific haemostatic abnormalities in children surviving septic shock with purpura and having skin necrosis or limb ischaemia that need skin grafts or limb amputations?
8. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. American college of critical care medicine
9. A myocardial cytotoxic process in involved in the cardiac dysfunction of meningococcal septic shock
10. Myocardial injury in meningococcus-induced purpura fulminans in children
11. Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases
12. Disseminated intravascular coagulation and purpura fulminans secondary to infection
13. Early management of meningococcal disease
14. Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease
15. Incidence of bacteremia in infants and children with fever and petechiae
16. Recognising meningococcal disease in primary care: Qualitative study of how general practitioners process clinical and contextual information
17. Sepsis in neonates and children: Definitions, epidemiology, and outcome
18. Avoidable deficiencies in the delivery of health care to children with meningococcal disease
19. The management of fever and petechiae: Making sense of rash decisions
20. Plasma procalcitonin levels correlated with the severity of systemic meningococcal disease in children
21. Emergency management of meningococcal disease
22. Avis du Conseil supérieur d'hygiène publique de France du 10 mars 2000 sur la conduite immédiate à tenir en cas de suspicion clinique de purpura fulminans et sur la définition des cas de méningite à méningocoque et de méningococcémie dans l'entourage desquels une prophylaxie doit être envisagée
23. Outcome of pre-hospital antibiotic treatment of meningococcal disease
24. Meningococcal disease in a large urban population (Barcelona, 1987-1992): Predictors of dismal prognosis
25. Antibiotic treatment of children with unsuspected meningococcal disease
26. Introduction of an automated service for the laboratory confirmation of meningococcal disease in Scotland
27. Scores de gravité à l'admission des méningococcémies
28. Can generic scores (PRISM, PIM) replace specific scores in predicting the outcome of presumed meningococcal septic shock in children?
29. Corticothéapie au cours du choc septique et du syndrome de détresse respiratoire aiguë
30. Admission cortisol and adrenocorticotrophic hormone levels in children with meningococcal disease: Evidence of adrenal insufficiency?
31. Endocrine and metabolic responses in children with meningoccocal sepsis: Striking differences between survivors and non survivors
32. Adrenal insufficiency in septic shock
33. Intravenous immunoglobulin for treating sepsis and septic shock
34. Hypocalcaemia in severe meningococcal infections
35. Recommandations pour la pratique clinique. Remplissage vasculaire au cours des hypovolémies relatives ou absolues
36. Utilisation des catécholamines au cours du choc septique (adultes-enfants)
37. Hemodynamic support in fluid-refractory pediatric septic shock
38. Quantitated left ventricular systolic mechanics in children with septic shock utilizing noninvasive wall-stress analysis
39. Clinical applications of wall-stress analysis in the pediatric intensive care unit
40. 21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
41. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia
42. Administration of protein C concentrate in children with severe meningococcal disease results in dose-related increases in serum protein C and activated protein C levels
43. Efficacy and safety of recombinant human activated protein C for severe
44. Use of tissue plasminogen activator in children with fulminant meningococcaemia
45. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease
46. Neurodevelopmental outcome in meningococcal disease : A case-control study
47. Prophylaxie des infections invasives à méningocoques. Circulaire n° DGS/SD5C/2001/542 du 8 novembre 2001
48. Fcγ receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children
49. Association of human FcγRIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease
50. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease
51. Variation in the tumor necrosis factor-α gene promoter region may be associated with death from meningococcal disease
52. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease
53. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock
54. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease
55. The insertion/deletion polymorphism in the t-PA gene does not significantly affect outcome of meningococcal disease
56. Effect of the factor V Leiden mutation on the severity of meningococcal disease